Name | 6-Amino-5-Bromoquinoxaline |
Synonyms | 5-bromoquinoxalin-6-amine 5-BROMO-6-QUINOXALINAMINE 5-Bromoquinoxalin-6-amine 5-Bromo-6-aminoquinoxaline 6-AMINO-5-BROMOQUINOXALINE 6-Amino-5-Bromoquinoxaline 5-bromo-6-amino quinoxaline 5-BroMoquinoxalin-6-aMine, 6-AMino-5-broMoquinoxaline Brimonidine Related Compound (5-Bromo-6-Aminoquinoxaline) |
CAS | 50358-63-9 |
EINECS | 807-712-8 |
InChI | InChI=1/C8H6BrN3/c9-7-5(10)1-2-6-8(7)12-4-3-11-6/h1-4H,10H2 |
Molecular Formula | C8H6BrN3 |
Molar Mass | 224.06 |
Density | 1.744±0.06 g/cm3(Predicted) |
Melting Point | 151-153°C |
Boling Point | 367.0±37.0 °C(Predicted) |
Flash Point | 175.8°C |
Vapor Presure | 1.4E-05mmHg at 25°C |
pKa | 0.33±0.30(Predicted) |
Storage Condition | Keep in dark place,Sealed in dry,Room Temperature |
Refractive Index | 1.747 |
MDL | A151240 |
Safety Description | 24/25 - Avoid contact with skin and eyes. |
HS Code | 29339900 |
Introduction | 6-amino-5-bromoquinoxaline is an important intermediate of quinoxaline derivatives, and its derivatives have obvious biological activity to the original organism. Compounds with similar structures have been found to be selective α2-adrenergic receptor stimulants. |
Use | 6-amino-5-bromoquinoxaline is an organic intermediate that can be used to prepare brimonidine tartrate. The chemical name of brimonidine tartrate (BrimonidineL-tartrate) is 5-bromo-N-(4, 5-dihydro-1H-imidazol-2-yl)-6-quinoxaline-L-tartrate. It is a new highly selective 2-adrenergic receptor agonist developed by Allergan Corporation of the United States. It was first listed in the United States in 1996 with a trade name of Alphagan. The drug's selectivity to α2-receptor is 7-12 times higher than clonidine and 23-32 times higher than apraclonidine. Its intraocular pressure lowering effect is similar to clonidine, stronger than apraclonidine, and is mainly used clinically for the treatment of new drugs for open-angle glaucoma. |
preparation | 6-aminoquinoxaline (14.52g,0.10mol) and CuBr2(2.23g,0.01mol) are added into hydrobromic acid aqueous solution (0.8mol/L,150mL), and oxygen (or air) is injected to maintain normal pressure, after reacting at 90~95 ℃ for 4 hours, the reaction solution is reduced to room temperature, the pH value of the reaction system is adjusted to 9 20% NaOH solution, dichloromethane (90mL) is extracted, purified water (50mL × 2) is washed, anhydrous sodium sulfate is dried, filtered, filtrated, filtrate is concentrated under reduced pressure, and vacuum drying at 40 ℃ to obtain 6-amino -5-bromoquinoxaline, yield: 97.8%,CHPLC purity: 99.94%. |